Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma

Journal of Immunotherapy

Volumn 39, Issue 3, 2016, Pages 149-152

  Nayar, Namrata ^a   Briscoe, Karen ^b   Penas, Pablo Fernandez ^c  

^a Central Coast Cancer Centre   (Australia)

^b Department of Paediatric Emergency Medicine   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Anti PD1 antibody; DRESS; Erythema multiforme; Metastatic melanoma; Nivolumab; Skin toxicity; Toxic epidermal necrolysis

Indexed keywords

B RAF KINASE; CYCLOSPORIN; IMMUNOGLOBULIN; IPILIMUMAB; MEPREDNISONE; NIVOLUMAB; PREDNISONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; STEROID;

ADULT; APOPTOSIS; ARTICLE; BLISTER; CASE REPORT; DERMATITIS; DERMOEPIDERMAL JUNCTION; DIARRHEA; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; EPIDERMIS; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; MACULOPAPULAR RASH; METASTATIC MELANOMA; MIDDLE AGED; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SATELLITE CELL; SKIN BIOPSY; SKIN TOXICITY; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; BIOPSY; COMPLICATION; DISEASE COURSE; DRUG RESISTANCE; FATALITY; MELANOMA; METASTASIS; PATHOLOGY; SKIN; STEVENS-JOHNSON SYNDROME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN; STEROIDS; STEVENS-JOHNSON SYNDROME;

EID: 84960155371     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000112     Document Type: Article

References (14)

1. Naidoo J, Page DB, Wolchok JD. Immune checkpoint blockade. Hematol Oncol Clin North Am. 2014;28:585-600.
2. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384.
3. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol. 2015;33:23-35.
4. Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72:221-236. quiz 237-228.
5. Lacouture ME,Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71:161-169.
6. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2015;33:15.
7. Danlos FX, Pages C, Roux J, et al. Atypical severe immunerelated adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Res. 2015;25:178-179.
8. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114:1209-1215.
9. Lee H-Y, Chung W-H. Toxic epidermal necrolysis: the year in review. Curr Opin Allergy Clin Immunol. 2013;13:330-336.
10. Kanitakis J. Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features. Eur J Dermatol. 2014;24:533-544.
11. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51:889-902.
12. Morito H, Ogawa K, Fukumoto T, et al. Increased ratio of FoxP3+ regulatory T cells/CD3+T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms. Clin Exp Dermatol. 2014;39:284-291.
13. Picard D, Janela B, Descamps V, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2:46.
14. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119-125.